Capricor Therapeutics Announces the Appointment of Karimah Es Sabar to its Board of Directors
July 27, 2021 08:00 ET
|
Capricor Therapeutics
LOS ANGELES, July 27, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based...
Capricor Therapeutics to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference
June 17, 2021 09:00 ET
|
Capricor Therapeutics
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based...
Capricor Therapeutics to Participate in BIO Digital 2021 Conference
June 10, 2021 09:15 ET
|
Capricor Therapeutics
LOS ANGELES, June 10, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the...
Capricor To Present Preclinical Data for Exosome-mRNA Vaccine for SARS-CoV-2 at the International Society for Extracellular Vesicles (ISEV) Annual Meeting
May 18, 2021 08:30 ET
|
Capricor Therapeutics
-Capricor’s Findings Support Expansion Across Multiple Therapeutic Targets- -Conference will be held virtually: May 18 – May 21- LOS ANGELES, May 18, 2021 (GLOBE NEWSWIRE) -- Capricor...
Capricor Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 13, 2021 16:05 ET
|
Capricor Therapeutics
---Requested Meeting with FDA to Discuss Next Steps in Development of CAP-1002 for Duchenne Muscular Dystrophy- -Data for Phase II INSPIRE Clinical Trial Expected in Third Quarter- -Plan to File IND...
Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
May 12, 2021 09:00 ET
|
Capricor Therapeutics
--Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery-- LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics to Present First Quarter 2021 Financial Results and Recent Corporate Update on May 13
May 06, 2021 08:30 ET
|
Capricor Therapeutics
LOS ANGELES, May 06, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the...
Capricor Therapeutics Signs Exclusive Worldwide License Agreement with Johns Hopkins University to Expand its Exosome Platform Technology Portfolio
April 29, 2021 08:00 ET
|
Capricor Therapeutics
LOS ANGELES, April 29, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for...
Capricor Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 11, 2021 16:01 ET
|
Capricor Therapeutics
Exosomes Platform Technology-Pre-IND Meeting with FDA this Quarter to Discuss Multivalent Exosome-mRNA Vaccine--Pipeline Expansion Underway Using Engineered Exosomes- Cell Therapy Program-In...
Capricor Therapeutics Announces New Advances in Exosome-Mediated mRNA Delivery Platform
March 09, 2021 09:15 ET
|
Capricor Therapeutics
-New Data Demonstrates Exosome-Mediated Delivery of mRNAs With Enhanced Expression and Lower Toxicity Compared to Lipid Nanoparticles- -Functional Enzyme Expression and Real-Time Imaging of mRNA...